Genetic deciphering of the antagonistic activities of the melanin-concentrating hormone and melanocortin pathways in skin pigmentation

Romain Madelaine; Keri J Ngo; Gemini Skariah; Philippe Mourrain

doi:10.1371/journal.pgen.1009244

. 2020 Dec 10;16(12):e1009244. doi: 10.1371/journal.pgen.1009244

Genetic deciphering of the antagonistic activities of the melanin-concentrating hormone and melanocortin pathways in skin pigmentation

Romain Madelaine ¹, Keri J Ngo ^1,², Gemini Skariah ¹, Philippe Mourrain ^1,^3,^*

Editor: Ian J Jackson⁴

PMCID: PMC7755275 PMID: 33301440

Abstract

The genetic origin of human skin pigmentation remains an open question in biology. Several skin disorders and diseases originate from mutations in conserved pigmentation genes, including albinism, vitiligo, and melanoma. Teleosts possess the capacity to modify their pigmentation to adapt to their environmental background to avoid predators. This background adaptation occurs through melanosome aggregation (white background) or dispersion (black background) in melanocytes. These mechanisms are largely regulated by melanin-concentrating hormone (MCH) and α-melanocyte–stimulating hormone (α-MSH), two hypothalamic neuropeptides also involved in mammalian skin pigmentation. Despite evidence that the exogenous application of MCH peptides induces melanosome aggregation, it is not known if the MCH system is physiologically responsible for background adaptation. In zebrafish, we identify that MCH neurons target the pituitary gland-blood vessel portal and that endogenous MCH peptide expression regulates melanin concentration for background adaptation. We demonstrate that this effect is mediated by MCH receptor 2 (Mchr2) but not Mchr1a/b. mchr2 knock-out fish cannot adapt to a white background, providing the first genetic demonstration that MCH signaling is physiologically required to control skin pigmentation. mchr2 phenotype can be rescued in adult fish by knocking-out pomc, the gene coding for the precursor of α-MSH, demonstrating the relevance of the antagonistic activity between MCH and α-MSH in the control of melanosome organization. Interestingly, MCH receptor is also expressed in human melanocytes, thus a similar antagonistic activity regulating skin pigmentation may be conserved during evolution, and the dysregulation of these pathways is significant to our understanding of human skin disorders and cancers.

Author summary

Melanocytes produce melanin, a natural skin pigment, for body coloration which helps to protect and camouflage an organism and to attract mates. Melanocytes are ubiquitous pigment cells in vertebrates and the genes underlying their development are well conserved, making fishes that possess the ability to modify their pigmentation, biologically relevant and successful models for human skin disorders. Many human skin diseases including albinism, vitiligo, and melanoma are derived from mutations in conserved pigmentation genes. However, much of the conserved molecular mechanisms behind these diseases and human pigmentation remain unknown. For instance, melanin concentrating hormone (MCH) was originally identified as a peptide that when injected, could make fish paler by promoting melanin aggregation but no mutants demonstrating an endogenous function for MCH in pigmentation have been reported. Here, we use zebrafish mutants of MCH and the MCH receptor to determine their specific genetic function in pigmentation. Additionally, we demonstrate that MCH has an antagonistic pigmentation function to the melanocortin system, where MCH expression promotes lighter pigmentation and melanocortin activity promotes darkening. Thus, we find that the balance between the MCH and melanocortin system activities are likely required for skin pigmentation and dysregulation of these pathways could underlie adverse human skin conditions.

Introduction

Skin pigments play a role in the protection, attraction, and camouflage of an organism. Body coloration, such as pigment color and patterning, is derived from specialized pigment cells called melanocytes. Melanocytes produce melanin, a natural skin pigment, that is responsible for human coloring of the skin, eyes, and hair. In human skin, these cells offer protection against DNA damaging UV rays. Although some animals have additional pigment producing cells, melanocytes are the ubiquitous pigment synthesizing cell type in vertebrate animals [1]. Defects in melanocyte function can lead to skin pigmentation disorders, including vitiligo, albinism, and melanoma [1–3].

The conservation of melanocyte and melanophore-regulating genes across vertebrates has made fishes biologically relevant and successful models for uncovering the molecular mechanisms regulating melanocyte related human diseases [2–4]. For instance, zebrafish studies uncovered the first genetic evidence explaining human inter-ethnicity skin differences. Mutations in SLC24A5, a gene that encodes a cation exchanger and is associated with the golden zebrafish mutant, make the largest known contribution to skin color differences between people of European, Asian, and African ancestry [5, 6]. The light skin color variation may be regarded as a contributor to skin cancer susceptibility [5, 6].

Fish and mammals also share hypothalamic neuropeptides capable of changing skin pigmentation such as the melanin-concentrating hormone (MCH) and α-melanocyte–stimulating hormone (α-MSH) [7–11]. However, their genetic influence is not fully understood. MCH was originally identified in salmon (Oncorhynchus keta) as a peptide that can regulate skin pigmentation by promoting the aggregation of melanosomes [7, 8]. Indeed, injection of exogenous MCH into the bloodstream made salmons grow paler. However, no MCH fish mutant has yet been reported demonstrating an endogenous function in pigmentation. We previously discovered that fish genomes encode two different MCH genes, Pmch1 and Pmch2, encoding MCH1 (17 amino acids) and MCH2 (19AA) respectively [12]. Whereas Pmch1 and its corresponding MCH1 peptide resemble MCH originally found in salmon (sMCH), we found that the Pmch2 gene and MCH2 peptide share genomic structure, synteny, and high peptide sequence homology with the mammalian MCH gene and peptide (mMCH) [12]. This finding confirmed the conservation of this pathway across vertebrates. However, the specific genetic functions in pigmentation of MCH1/sMCH and MCH2/mMCH peptides remain unclear.

Where MCH expression promotes lighter pigmentation, the α-MSH/melanocortin system has the opposite effect in fish and mammals [13]. The melanocortin-1 receptor (MC1R) is a G-protein coupled receptor (GPCR) primarily located on melanocytes that regulate cAMP/protein kinase A (PKA) response through the binding of α-MSH encoded by the proopiomelanocortin (POMC) gene [14–16]. In mammals, MC1R signaling determines the amount of melanin pigment synthesized, affecting skin pigmentation [17]. Similarly, in fish and amphibians, α-MSH hormone peptides bind to MCRs to stimulate physiological body color changes [3, 18]. Contrary to MCH, α-MSH which is mainly expressed in the posterior part of the pituitary gland promotes the dispersion of melanosomes to regulate background adaptation [3, 18]. Interestingly, it has also been suggested that hypothalamic MCH peptide is released at the pituitary gland to inhibit the release of α-MSH [19, 20]. Because MCH decreases intracellular cAMP level while α-MSH increases it [3, 18], the balance between the activities of these two peptides is a key component of melanosome organization by microtubules and the actin cytoskeleton. Meanwhile, in human melanocytes this antagonistic activity is observed at the level of pigment production and not aggregation: α-MSH stimulates melanogenesis and MCH inhibits it [21]. These observations point to a conserved antagonistic relationship between α-MSH and MCH, whereby α-MSH promotes darker pigmentation and MCH promotes lighter pigmentation.

Still, genetic evidence demonstrating an endogenous role for the MCH pathway and its antagonistic interaction with α-MSH in vertebrate skin pigmentation are lacking. Here, we generated zebrafish mutants of the three MCH receptor genes (MCHR) as well as transgenic lines to control MCH peptides expression. We genetically demonstrate for the first time that the MCH system controls skin pigmentation in zebrafish. We revealed that both MCH1 and its paralogous peptide conserved in mammals, MCH2/mMCH, can regulate melanosome contraction. This effect is mediated through Mchr2 activity but not Mchr1a and 1b. mchr2 and pomc double mutants also reveal epistatic interactions demonstrating in vivo that MCH and α-MSH have antagonizing roles in regulating background adaptation. Based on the conservation of MCH2/mMCH and α-MSH peptides and their receptors from fish to mammals, our findings uncover further genetic evidence of the antagonistic functions between the MCH and the melanocortin systems in vertebrate melanocyte homeostasis. It also suggests that their dysregulation could be part of the abnormal processes underlying human skin disorders such as vitiligo and melanoma.

Results

Mch axons projects to the pituitary gland

The zebrafish genome encodes three orthologues of MCH receptors (MCHR) [21]. Both mchr1a and mchr1b genes are broadly expressed in the brain, while mchr2 expression is specifically detected in skin melanocytes [12], suggesting a unique function for this receptor in skin pigmentation and background adaptation. However, the specific functions of the zebrafish MCH1 (similar to the salmon MCH) and MCH2 (similar to the mammalian MCH) peptides, and how the MCH signal can be transmitted from the brain to the MCHR expressed in the skin remained unclear.

We previously showed that the Pmch1 and Pmch2 genes are expressed in neurons located in the hypothalamus that project throughout the brain around the ventricles [12] to likely connect to MCHR1a and MCHR1b expressing neurons. In addition to the dense projections in the ventral telencephalon, thalamus, and posterior tuberal nucleus [12], we found the existence of hypothalamic MCH fibers that extended toward the pituitary gland in the adult zebrafish brain (Fig 1A). However, as the adult pituitary is enclaved in a bone structure, it was lost in the brain tissue preparation and the actual connection of the MCH neurons to the pituitary was still unclear. Nevertheless, using an MCH antibody, we were able to show that the MCH peptide is present on the pituitary isolated from the adult zebrafish brain, revealing synaptic glomeruli-like structures (Fig 1B). Altogether, these observations show that hypothalamic MCH neurons can target the pituitary gland, suggesting a potential pathway via the blood stream to distribute the MCH peptide through the organism. To confirm the above hypothesis and reveal the entire MCH innervation on the pituitary gland, we used the zebrafish Pmch2 gene promoter and we generated a stable Tg(mch2:egfp) reporter line (Fig 1C and S1 Fig). In the zebrafish Tg(mch2:egfp) larvae, we observed bright EGFP+ cell bodies in the lateral hypothalamus of both hemispheres that send converging projections to the ventral midline and densely innervated the pituitary gland. Further, mosaic EGFP expression in a single MCH neuron showed that axonal extensions innervate the pituitary at multiple points (S1(B) Fig). Consistent with these neuronal projections, using an MCH antibody [12], we showed similar projections and that the MCH peptides are preferentially accumulated on the pituitary gland, at the hypothalamo-neurohypophysis interface (Fig 1D, S1(D) and S1(E) Fig). This is reminiscent to other known pituitary peptides such as α-MSH and oxytocin (Fig 1E and 1F), where the α-MSH antibody stains cells in the posterior pituitary and the oxytocin antibody stains axons targeting the neurohypophysis [22]. This data validated the physical interaction between MCH neurons and the pituitary gland in zebrafish (Fig 1B–1F) as originally observed in salmon [8].

Fig 1 — **(A-B)** Confocal projection of immunolabelling with MCH in the adult zebrafish brain (A) and pituitary gland (B). The outline area represents the hypothalamic MCH projection at immediate vicinity of the adult zebrafish pituitary, lost during the tissue preparation. **(C, D)** Confocal projection of immunolabelling with EGFP in *Tg(mch2:egfp)* hypothalamus (C) or with the MCH2 antibody (D) at 5 dpf, reveals that MCH2 neurons in the hypothalamus have axonal projections on the pituitary gland. **(E, E’)** Confocal projection of double immunolabelling with MCH2 and α-MSH at 7 dpf, showing MCH cellular projections on the α-MSH+ domain (E). Schematic representation of the ventral part of the zebrafish brain showing the hypothalamic neurons expressing MCH2 targeting the posterior part of the pituitary gland expressing α-MSH (neurohypophysis) (E’). **(F)** Confocal projection of double immunolabelling with Oxtl and EGFP in *Tg(mch2:egfp)* hypothalamus at 7 dpf, demonstrating that MCH neurons target the neurohypophysis. **(G, G’)** Confocal projection of double immunolabelling with MCH2 and blood vessels at 5 dpf, suggesting that MCH peptide can be released in the bloodstream (G). Schematic representation of the ventral part of the zebrafish brain showing the hypothalamic MCH2 terminal projections targeting the neurohypophysis surrounded by blood vessels (Hypothalamo-Hypophyseal system) (G’). Ventral (A-C) or (D-F) dorsal view with anterior up. Scale bars: 50 μm (A) or 10 μm (B-G).

As the pituitary gland from fishes to mammals can be used as a portal to the body vasculature, this observation suggested a potential way in which MCH can control skin pigmentation of peripheral tissues via the bloodstream. To assess this possibility, we used an antibody for the vascular endothelial receptor marker, Kdrl, to visualize the surrounding vasculature architecture. We observed that the MCH peptides were nested in a ring-like vascular structure (Fig 1G and 1G’). The close proximity of MCH projections with blood vessels suggest that MCH peptides could indeed be released into the bloodstream via the pituitary to control a variety of physiological functions throughout the body.

Mch1 and Mch2 overexpression reduce skin pigmentation

To investigate the role of both MCH1 and MCH2 peptides in the control of skin pigmentation, we generated two stable transgenic lines that express mch1 and mch2 after heat-shock; Tg(hs:mch1) and Tg(hs:mch2). Because MCH peptide expression is known to increase when the fish is white adapted [12, 23], we raised these larvae on a black background to assess the activity of these peptides in the pigmentation process. After heat-shock, both MCH1 and MCH2 induced expression reduced melanosome dispersion even on a dark background (Fig 2A, 2B and 2C). We observed a reduction of 45% in skin pigment coverage after the induction of MCH expression compared to control larvae that do not carry the transgene but are also heat-shocked (Fig 2D). This result indicates that MCH2, like MCH1, can lead to paler skin when overexpressed and suggests that both peptides could bear redundant activity in the control of skin pigmentation and the physiological regulation of melanosome organization and background adaptation.

Fig 2 — **(A-C)** Dorsal melanocytes of control (A), *Tg(hs:mch1)* (B) or *Tg(hs:mch2)* (C) black adapted larvae at 7 dpf following heat-shock. **(D)** Melanosome coverage was quantified in control, *Tg(hs:mch1)* or *Tg(hs:mch2)* in region of interest (ROI). The ROI has been defined as an area from the posterior of the eyes to the posterior of the hindbrain. Error bars represent s.d. *P<0.05, **P<0.001, ***P<0.0005, determined by t-test, two-tailed.

MCHR2 is required for melanosome aggregation and background adaptation

We next sought to uncover the mechanism by which the MCH peptides induce changes in melanosome organization. MCH peptides act via MCH receptors, a type I G-protein coupled receptor [19, 24]. Both mchr1a and mchr1b zebrafish genes are broadly expressed in the brain, while mchr2 expression is specifically detected in the skin melanocytes from an early stage of larval development [12]. Humans have two MCH receptors, MCHR1 and MCHR2 [25], that are also largely expressed in the brain, but only MCHR1 expression has been shown in human melanocytes [10]. These observations indicate that MCHR expression in melanocytes is conserved across vertebrates, from human to zebrafish. While the MCHR1 receptor is known to be expressed in human skin and cultured melanocytes [10], suggesting a conservation of the function across vertebrates, a direct role of MCH receptors in controlling skin pigmentation has not previously been reported. To have a better understanding of the function of the MCH system in the regulation of skin pigmentation and background adaptation, we used a set of knock-out mutants for the three MCH receptors in zebrafish. We generated the mchr1a and mchr2 mutants using the genome editing technique CRISPR/Cas-9, whereas the mchr1b mutant was generated by reverse genetics using TILLING. The mchr1a mutant harbors a small deletion of 4 bp, leading to a frameshift in the open reading frame (ORF) and the appearance of a premature stop codon (S2(A) Fig), while the mchr1b mutant carries a point mutation also leading to a premature stop codon (S2(B) Fig). To knock-out the mchr2 gene, we generated a deletion of 4 nucleotides leading to a premature stop codon in the ORF (Fig 3A). To address the function of the MCH pathway in skin pigmentation we used a combination of these 3 MCH receptor mutants.

Fig 3 — **(A)** Schematic representation of the *mchr2* locus and the small genomic deletion induced by CRISPR/Cas-9 leading to a premature stop codon in the mchr2 coding sequence. **(B, C)** Dorsal melanocytes of control (B) or *mchr2* homozygous mutant (C) black adapted larvae at 7 dpf. **(D)** Melanosome coverage was quantified in control or *mchr2* homozygous mutant black adapted larvae at 7 dpf in ROI, an area from the posterior of the eyes to the posterior of the hindbrain. **(E, F)** Dorsal melanocytes of control (E) or *mchr2* homozygous mutant (F) white adapted larvae at 7 dpf. **(G)** Melanosome coverage was quantified in control or *mchr2* homozygous mutant white adapted larvae at 7 dpf. **(H, I)** Larval and adult *mchr2* homozygous mutant phenotypes are characterized by melanosome dispersion on a white background, indicating that MCH signaling is required to promote melanosome contraction in melanocytes. Dorsal view with anterior up (B, C, E, F and H). Lateral view (I). Error bars represent s.d. *P<0.05, **P<0.001, ***P<0.0005, determined by t-test, two-tailed.

Through in situ hybridization, we previously showed that larval skin lacked mchr1a and mchr1b gene expression [12]. However, it remained possible that our detection method lacked the sensitivity required to truly capture the expression of these MCH receptors; thus, we observed the effects of knocking out mchr1a and mchr1b on larval skin to ensure that they were not involved in skin pigmentation. As expected, both mchr1a and mchr1b single homozygous mutants did not show any defects in skin pigmentation or background adaptation. To assess if there was partial redundant expression and function of these two receptors that was causing a normal phenotype in the single knock-out mutants, we crossed single mutants to generate a double mutant for mchr1a and mchr1b. The double mutant also showed normal skin pigmentation and adaptation to a white background (S2(C), S2(D) and S2(E) Fig), suggesting that MCH signaling in melanocytes is still functional in this genetic context. While we cannot totally exclude that one of these mchr1 mutants is not a null allele despite the presence of premature stop codons in their ORFs, these results strongly suggest that mchr1a and mchr1b are not involved in the control of melanosome concentration and skin pigmentation.

After excluding a role for mchr1a and mchr1b in the regulation of skin pigmentation and melanosome organization, we hypothesized that due to the restricted expression of MCHR2 in melanocytes [12], and its sequence conservation with the human MCHR1 expressed in the skin (S2(F) Fig), MCHR2 may be the functional effector of the MCH pathway in the control of skin pigmentation. Strikingly, the mchr2 mutant shows an increase of 75% in skin pigment coverage when raised on a black background (Fig 3B, 3C and 3D). In this mutant, melanocytes harbor an extensive dispersion of the melanosomes in the cell, indicating a potent inactivation of MCH signaling. Additionally, the mchr2 mutant is not able to adapt to a white background as larvae (Fig 3E–3H; 200% increase in pigment coverage in the mutant) and as adults (Fig 3I), revealing that MCH signaling is a critical component of the background adaptation system throughout life. Finally, mch1 or mch2 overexpression in the mchr2 mutant background failed to rescue the pigmentation phenotype or reduce melanin dispersion (Fig 4A–4E). This result demonstrates that MCH peptides need functional MCHR2 in melanocytes to promote melanin concentration. In addition, it supports the observation that MCHR1a and MCHR1b do not have compensatory functions in skin pigmentation control. Altogether, these data provide the first genetic evidence that demonstrate the direct physiological role of MCH receptors in the control of melanosome organization in vertebrates.

Fig 4 — **(A-D)** Dorsal melanocytes of control (A), *mchr2* homozygous mutant (B), *mchr2* homozygous mutant; *Tg(hs:mch1)* (C) or *mchr2* homozygous mutant; *Tg(hs:mch2)* (D) black adapted larvae at 7 dpf following heat-shock. **(E)** Melanosome coverage was quantified in control, *mchr2* homozygous mutant, *mchr2* homozygous mutant; *Tg(hs:mch1)* or *mchr2* homozygous mutant; *Tg(hs:mch2)* larvae at 7 dpf. Dorsal view with anterior up. Error bars represent s.d. *P<0.05, **P<0.001, ***P<0.0005, determined by t-test, two-tailed.

Antagonistic activity between MCH and α-MSH controls skin pigmentation

In the mchr2 mutant where MCH signaling is abolished in melanocytes, we observed an increase in skin pigment coverage. However, mchr2 mutants show normal tyrosinase expression levels in melanocytes (S3(A) and S3(B) Fig), suggesting that these cells develop normally in this mutant. It also suggests that the pigmentation phenotype is not due to an increase in melanin synthesis. In addition, it has been previously shown that α-MSH induces melanosome dispersion [3, 18, 26] and in the melanocortin-1 receptor (mc1r) knock-down, there is inhibited melanosome dispersion in zebrafish [22]. Altogether, these observations led us to hypothesize that because MCH signaling is not functional in mchr2-/- melanocytes, the melanocortin pathway (POMC/α-MSH-MC1R) is responsible for inducing melanin dispersion.

We next asked how α-MSH, cleaved from the proopiomelanocortin precursor (POMC), may be involved in the skin pigmentation defects observed in the mchr2 mutant. Teleosts possess two POMC paralogs, pomca and pomcb, originating from an ancient whole-genome duplication event [27]. During teleost evolution, the expression domains of the pomc paralogs underwent a process of sub-functionalization, partitioning pomca expression to the pituitary gland and the ventral hypothalamus while pomcb expression was partitioned to the brain preoptic area [27–30]. Based on these different expression patterns, we chose to focus on pomca, reasoning that the pomca paralog was more likely to be the α-MSH precursor within the pituitary. In the mchr2 knock-out, we did not detect any variation in the expression of pomca mRNA or α-MSH small peptides (S3(C)–S3(F) Fig), suggesting that the melanocortin pathway could be responsible for the skin pigmentation phenotype. Supporting this hypothesis, α-MSH expression promotes melanosomes dispersion [3, 18], a phenotype reminiscent to the mchr2 mutant, indicating that POMC/α-MSH activity may be responsible for the melanosome organization and background adaptation defects observed in the mchr2 mutant.

To investigate the role of pomc in the pigmentation process in the mchr2 mutant, we generated a knock-out of the pomca gene (Fig 5A–5C’), the only precursor of α-MSH which is expressed in the pituitary gland (S3(G) and S3(H) Fig). The mutant allele carries two deletions generated by CRISPR/Cas9 editing (one in each coding exon of the pomca ORF; Fig 5A). Double immunolabeling with α-MSH and MCH antibodies confirms that the pomca homozygous mutant lacks α-MSH expression but still maintains MCH expression when compared to control sibling larvae, suggesting impaired melanocortin signaling (Fig 5B–5C’). Consistent with the previously described phenotype of mc1r depletion [22], pomca mutant larvae are not able to adapt to a black background (Fig 5D and 5E), as shown by a reduced skin pigmentation coverage of 50% compared to control siblings (Fig 5F). Moreover, reported mc1r mutants have disrupted dorso-ventral countershading. Where fish normally have a dark dorsum and a light ventrum, the mc1r mutants have hyperpigmented ventrums and less dorsal melanophores [31, 32]. Unlike these mc1r knock-outs, the pomca knock-outs have relatively normal countershading as they display dark dorsums (S4(A)–S4(D) Fig) and white ventrums (S4(E) and S4(F) Fig). Differences in the number of dorsal melanophores and xanthophores were found to be statistically insignificant (S4(G) Fig), indicating that the observed pigmentation changes are indeed predominantly due to background adaptation.

The skin pigmentation phenotype of the pomca-/- mutant is reminiscent to the pigment phenotype when MCH is overexpressed (Figs 2A–2D and 5D–5F), indicating that the loss of α-MSH function leads to a predominant activity of the MCH system. Interestingly, the knock-out of pomca in the mchr2 mutant does not rescue the mchr2 mutant phenotype as double mchr2-/-, pomca-/- mutant larvae are not able to adapt to a white background and they maintain extensive melanosome dispersion (Fig 5G–5J) more akin to a black adapted phenotype (Fig 5D). This result indicates that additional factors other than α-MSH can promote melanosome dispersion in the mchr2 mutant genetic background in larvae.

Surprisingly, in juvenile and adult fish, the mchr2-/-, pomca-/- double mutant phenotype appears to be different than in larvae. Indeed, starting at about 1-month post fertilization, we observe that skin pigmentation in the mchr2-/-, pomca-/- double mutant is no longer identical to the mchr2 mutant, and becomes reminiscent to the pomca-/- phenotype in adults (Fig 6A–6D). Strikingly, adult double mutants are not able to adapt to a black background and harbor a pattern of pigmentation similar to pomca mutant fish where striped patterning is lighter than the stripes of mchr2 mutants (Fig 6E–6H). These observations indicate that the inability of the adult mchr2 mutant to adapt to a white background is due to the predominant activity of the melanocortin pathway, and that abolishing this signaling is sufficient to promote melanosome contraction in the mchr2 homozygous mutant. Altogether, these data bring functional evidence to demonstrate that the antagonistic activity between MCH and melanocortin signaling is a major regulator of melanosome organization, skin pigmentation, and reveals a different mode of interaction between these two pathways during development and adult life.

Fig 6 — **(A-D)** Loss of function phenotype on skin pigmentation from white adapted adult control **(A)**, *pomca* **(B)**, *mchr2* **(C)** or double *mchr2; pomca* **(D)** homozygous mutant. **(E-G)** Loss of function phenotype on skin pigmentation from black adapted adult control **(E)**, *pomca* **(F)**, *mchr2* (G) or double *mchr2; pomca* **(H)** homozygous mutant. Similar to the *pomca* homozygous mutant, *pomca; mchr2* double homozygous mutant phenotype is characterized by melanosome contraction on a black background, indicating that *pomca* loss of function is sufficient to allow melanosome contraction in absence of MCH signaling in adult zebrafish. Lateral view (E-G).

Discussion

This study genetically demonstrates that the MCH and the α-MSH/melanocortin systems interact to control skin pigmentation in zebrafish and likely all vertebrates. Through fluorescent labeling studies, we show a tight spatial association of MCH peptides with the pituitary blood portal, suggesting neuropeptide release into the peripheral circulation whereby body wide responses can be induced. We and others have demonstrated that both MCH1 and MCH2 expression increase when the fish is white adapted, indicating a physiological role in the control of background adaptation for these peptides [12, 23]. Here we show that much like MCH1, overexpression of MCH2 can reduce skin pigmentation in zebrafish, raising the possibility that the same gene in mammals could also affect pigmentation. In mammals, due to redundant pigmentation systems, it is possible that the disrupted gene is not sufficient to cause a skin disorder but instead can worsen pathology and the outcome of the disease. Additionally, of the MCH receptor mutants, only the mchr2-/- knockout displayed a changed pigment phenotype. Thus, released MCH peptides require functional MCHR2 but not MCHR1a or MCHR1b to affect melanosome organization, indicating that MCHR2 can relay signals from both MCH peptides. Contrary to zebrafish, MCHR2 expression in humans was not detected in skin tissues or melanocytes [10]. Since zebrafish MCHR2 is homologous to human MCHR1 and MCHR2, it is likely that despite bearing the same signal transduction, over the course of evolution from teleosts to mammals, the expression patterns of the MCH receptors were swapped.

Consistent with the idea that the MCH and the α-MSH/melanocortin systems act antagonistically to each other, the pomca-/- larval phenotype resembles the MCH1 and MCH2 overexpression phenotype where skin pigmentation is reduced. The pomca-/- mutant remains pale throughout its life; whereas, the mchr2-/- retains dark pigmentation, and both mutants lose their ability for background adaptation, indicating that both the melanocortin and MCH systems are required for the oscillation between melanosome dispersion and contraction. Several human skin pigmentation disorders and diseases originate from irregularities in melanocyte development and function. However, the causal relationships between the MCH and α-MSH regulatory systems and prevalent skin diseases such as melanoma and vitiligo are still poorly understood.

Melanoma is the most lethal skin disease originating from abnormalities in melanocyte development. The α-MSH receptor, MC1R, is expressed in skin cells like melanocytes [33], and variants in MC1R are known risk factors for melanoma [17]. Indeed, previous clinical studies indicate that there is a correlation between increased α-MSH levels and melanoma progression [34, 35]. Although no direct role for MCH in melanoma has been identified, MCHR1 has been found to be expressed in human melanocytes and melanoma cells [36], potentially allowing for MCH signaling to occur. The highly conserved interactions between the MCH and melanocortin pathways in controlling the development and function of melanocytes introduces the possibility that MCH variants might also be risk factors for melanoma, whereby changes in MCH affect POMC/α-MSH signaling.

In humans, vitiligo is a skin depigmentation disease caused by the loss of melanocytes [37]. The causes of the disease are not fully understood, but because vitiligo patients present autoantibodies and autoreactive T lymphocytes against melanocyte antigens, an autoimmune theory has been proposed [36]. In some cases, autoantibodies against MCHR1 were found in the serum of vitiligo patients and it has been hypothesized that they can modulate receptor activity [38, 39]. Indeed, MCHR1 autoantibodies have been shown to block the binding of MCH peptide with MCHR1 in a competitive manner and/or inhibit the activation of the receptor by blocking the release of intracellular calcium in response to MCH [39]. The authors hypothesized that the blocking of MCHR1 activity may affect normal melanocyte behavior via the lack of α-MSH downregulation. In mammals, α-MSH is known to positively regulate melanin synthesis [37] and because increase in melanin synthesis can lead to melanocyte death [37, 40, 41], the maintenance of a physiological balance between MCH and POMC/α-MSH signaling is likely critical to the skin pigmentation process. Altogether, these observations and our study, support the notion that the antagonistic activity between MCH and the melanocortin system is a master regulator of the melanosome organization conserved across vertebrates.

Surprisingly though, we observed that abolishing the opposing functions of MCH and α-MSH does not lead to the same phenotype in larvae and adults, revealing that their antagonistic activity is not integrated in the same manner during development. The pomca/mchr2 double knock-out mutant lacks the ability for background adaptation and has dark pigmentation in the larval stage akin to the mchr2-/- single mutant phenotype. However, the pigmentation of the mchr2/pomca double mutant becomes paler in adulthood, resembling the pomca-/- single mutant. One possible explanation for this discrepancy is the redundant activity with other molecular factors that are expressed differentially during life, like sexual maturation hormones or other neuropeptidergic signals. For example, in young fish, it is possible that additional uncovered neuropeptides control melanosome organization and have redundant activity with the melanocortin system, thus preventing the rescue of the mchr2-/- phenotype via the loss of pomca function. However, in adults, our results indicate that the pomca knock-out phenotype is dominant over the mchr2 mutant phenotype, suggesting that additional factors besides MCH can control melanosome contraction.

Such factors could include other melanocortin receptor antagonists like agouti signaling protein (Asip) and agouti-related protein (Agrp) or other signaling pathways. It was reported that mutations in galanin signaling downregulates peripheral levels of thyroid hormones, leading to fewer stripes and paler appearance [42]. Importantly, galanin and MCH have both been involved in sleep and pigmentation regulation further suggesting common physiological functions and targets [42, 43]. Conceivably, combined pigmentation effects in multiple signaling pathways like galanin and melanocortin signaling could cause different phenotypes during development. In mammals, asip has been extensively reported to be expressed in dermal papillae cells and to be involved in pigmentation by competing with α-MSH for MC1R and MC4R binding and causing subsequent changes in melanin composition [44–48]. It has also been reported that asip can affect melanocyte differentiation and maturation in mice [49]. Meanwhile, mammalian agrp is mainly expressed in the hypothalamus where it has predominantly been explored in the context of regulating energy balance [50, 51]. In contrast to tetrapods, teleosts have four endogenous antagonists: asip1, asip2, agrp1 and agrp2 due to genome duplication [52, 53]. Previous studies in fish have shown that asip1, agrp1, and agrp2 are expressed in the skin and brain [54–56], where asip1 and agrp2 are expressed in the pineal gland and agrp1 is expressed in the hypothalamus, making them promising candidate factors for the regulation of melanosome organization in background adaptation.

Supporting the previous observation, injection of asip1 mRNA induces dorsal skin paling in multiple fish species and can reduce tyrosinase-related protein-1 (tyrp1) expression, a key enzyme in melanin synthesis [52, 57]. Moreover, in medaka (Oryzias latipes), asip1 has been found to inhibit α-MSH-induced melanosome movement via Mc1r binding competition [55]. Agrp2 also antagonizes Mc1r and previous demonstration has shown that agrp2 is required for melanin concentration [23], raising the possibility that asip1 and/or agrp2 may be able to promote melanosome concentration in the double mchr2/pomca mutant. In this case, our observations also suggest that Asip1 or Agrp2 activity alone is not sufficient to induce melanosome contraction and to antagonize the melanocortin signaling in the mchr2 mutant; either because it acts partially through Mchr2 signaling likely via mch1 and mch2 upregulation [23]; or because MCH and Asip1/Agrp2 activity need to synergize to counteract the melanocortin pathway. The function of Asip and Agrp peptides remains to be examined in the context of the antagonistic actions of the MCH and α-MSH/melanocortin systems in melanosome organization, where they may have a conserved role in vertebrate pigmentation and in the etiology of skin disorders.

Due to frequent dimerization among GPCRs [58, 59], we cannot exclude the possibility that heterodimerization of the MCR subtypes contribute to the observed discrepancy in skin phenotype. While there is no direct evidence that there is cross-binding between MCH and the melanocortin ligands with their receptor subtypes or that the ligands competitively inhibit each other’s binding to their respective receptors [13], some studies suggest that MCH may have some affinity for MC5R since high concentrations of MCH can mimic the effects of α-MSH in tissues and cell cultures expressing MC5R [60]. Indeed, there have been previous reports that MCH exhibits self-antagonistic, MSH-like activity at high concentrations in teleost melanophores whereby pigment dispersion is induced [61, 62] via an unknown mechanism. Although pigmentation is not mainly attributed to MC5R activity as it is with MC1R, MC5R is weakly expressed in the brain and is widely distributed in more peripheral regions like in the skin [63, 64] and is able to heterodimerize to MC1R [65]. It has been reported that MC1R/MC5R heterodimerizations weakens α-MSH signaling by inhibiting cAMP accumulation and that this ligand-selective receptor complex may be able to influence color changes in teleosts [65]. Thus, reduced α-MSH signaling and the self-antagonistic MCH pigment activity could be explained by competitive binding of MCH and α-MSH for the MC1R/MC5R heterodimer and this mechanism is contributing to the different phenotypes observed in the pomca/mchr2 double knock-outs throughout development. Additionally, studies have shown that mammalian MCRs can dimerize [66–68], leading to the possibility that MC1R/MC5R dimers appear in amniotic vertebrates and can similarly affect pigmentation through balancing MCH and α-MSH activities.

As skin pigmentation regulation is critical for many aspects of animal life including UV protection, camouflage, mimicry, aposematism (warning coloration) and sexual selection/reproduction fitness, to name a few, its precise regulation very likely requires a complex interplay of signals from the brain and body. Commonalities across vertebrates and amenable fish genetics continues to reveal the depth of these conserved mechanisms.

Materials and methods

Fish lines and developmental conditions

Ethics statement

Embryos were raised and staged according to standard protocols [69]. Our IACUC animal protocol (#9935) is approved by the American Association for the Accreditation of Laboratory Animal Care (AAALAC) in accordance with Stanford University animal care guidelines.

Tg(kdrl:ras-mCherry) [70] was used to visualize blood vessels. mchr1b mutant was generated by the zebrafish mutation project (Sanger Institute) and obtained from the ZIRC. Heat-shocks were performed in a water bath at 37°C for 1 hour. Embryos were fixed overnight at 4°C in 4% paraformaldehyde/1xPBS, after which they were dehydrated through an ethanol series and stored at −20°C until use.

CRISPR/Cas-9 generation of zebrafish mutants

To generate mchr1a, mchr2 and pomca mutants, we took advantage of the previously described genome editing method [71]. We used gRNA targeting the ORF (mchr1a: 5’-GTATGTGGCTACTGTCCACC-3’, mchr2: 5’-CAATCTACGGCGTCCTGTGC-3’ and pomca: ex1-5’-GAGGATGTTGTGTCCTGCT-3’ and ex2-5’-GTGGGGCAAACCGGTCGG-3’). Co-injection of these gRNA with the Cas9 mRNA resulted in small deletions. F0 carriers for the deletion in the germline were identified by sequencing of the alleles on the clutches and outcrossed to obtain F1 heterozygous mutants. F2 mutants homozygous for the deletion were also identified by sequencing. Our pomca knock-out carries the homozygous mutant allele containing both deletions.

Plasmid construction and transgenic line establishment

For the generation of Tg(mch2:egfp), 5kb of the zebrafish mch2 promoter was amplified by PCR on genomic DNA and was cloned in the p5E 5’ entry vector of the tol2kit. For the generation of heat-shock lines, mch1 and mch2 ORF were amplified by PCR from zebrafish cDNA and cloned in the pME middle entry vector. The appropriate entry and middle entry clones were mixed with the SV40pA 3’ entry vector and recombined into the Tol2 transposon destination vector. To establish stable transgenic lines, plasmids were injected into one-cell stage embryos with the Tol2 mRNA transposase [72].

In situ hybridization and immunostaining

In situ hybridizations were performed as previously described [73]. tyrosinase (tyr) pomca and pomcb ORF was cloned in a pCS2+ vector using zebrafish cDNA and antisense DIG labelled probes were transcribed using the linearized pCS2+ plasmid containing the ORF. In situs were revealed using either BCIP and NBT (Roche) or Fast Red (Roche) as substrates. Immunohistochemical stainings were performed as previously described [74], using either anti-GFP (1/1000, Torrey Pines Biolabs), anti-α-MSH (1/10000, Millipore), anti-OXT (1/500, Bachem) or anti-MCH (1/500, Phoenix Pharmaceuticals) as primary antibodies and Alexa 488 or Alexa 555-conjugated as secondary antibodies (1/1000, Molecular Probes).

Image acquisition and quantification of pigmentation coverage

Confocal acquisitions were carried out using a Leica SP5 confocal microscope (Stanford Cell Science Imaging Facility) and melanosomes were imaged using light microscopy. Images were prepared using Photoshop software (Adobe). For quantification of pigment coverage, images were analyzed using ImageJ software. Statistical analyses associated with each figure are reported in the figure legends.

Melanophore and xanthophore counts

Following previously reported protocols in adult fish [31, 32], melanophores and xanthophores cells were counted in 1 mm² regions in the dorsal area from the edge of the head to the dorsal fin. To contract melanosomes, fish were anesthetized in tricaine and immersed in 10 mg/ml epinephrine (Sigma) solution for 30 min. Images were analyzed using ImageJ software. Data are expressed as mean ± standard error of the mean (SEM) and evaluated by t-test, where a p-value<0.05 was determined to be statistically significant. n = 2 fish per category.

Supporting information

S1 Fig. mch2 reporter line demonstrates that Mch axons reach the pituitary gland.

(A, B) Confocal projection of immunolabelling with EGFP in Tg(mch2:egfp) hypothalamus at 5 (A) or 3 (B) dpf, reveals that MCH2 neurons in the hypothalamus have axonal projections on the pituitary gland. (C) Confocal section of double immunolabelling showing overlap in the expression of endogenous MCH2 peptides and EGFP in Tg(mch2:egfp) at 5 dpf. (D, E) Confocal projection of immunolabelling with EGFP in Tg(mch2:egfp) (D) or with MCH2 (E) at 7 dpf, showing identical projection patterning of MCH2 neurons on the neurohypophysis with both tools. Ventral view with anterior up. Scale bars: 10 μm.

(TIF)

Click here for additional data file.^{(1.9MB, tif)}

S2 Fig. mchr1a and mchr1b are not involved in melanosome organization.

(A) Schematic representation of the mchr1a locus and the small genomic deletion induced by CRISPR/Cas-9 leading to a premature stop codon in the mchr1a coding sequence. (B) Schematic representation of the mchr1b locus and the nucleotide substitution leading to a premature stop codon in the mchr1b coding sequence. (C, D) Dorsal melanocytes of control (C) or mchr1a; mchr1b double homozygous mutant (D) white adapted larvae at 7 dpf. (E) Melanosome coverage was quantified in control or mchr1a; mchr1b double homozygous mutant white adapted larvae at 7 dpf. Dorsal view with anterior up. (F) Amino acids sequence alignment between the zebrafish Mchr2 and the human MCHR1 proteins. The highlighted sequence shows the conservation of the G-protein receptor domain. Dorsal view with anterior up. Error bars represent s.d. *P<0.05, **P<0.001, ***P<0.0005, determined by t-test, two-tailed.

(TIF)

Click here for additional data file.^{(1.6MB, tif)}

S3 Fig. pomca expression in the posterior pituitary gland.

(A, B) Whole-mount in situ hybridization against tyrosinase (tyr) in larvae at 3 dpf, showing that melanocyte organization appears to be normal in the mchr2 homozygous mutant. (C, D) Whole-mount in situ hybridization against pomca in larvae at 5 dpf, showing that pomca expression appears to be normal in the mchr2 homozygous mutant. (E, F) Confocal projection of immunolabelling with α-MSH, showing that α-MSH expression appears to be normal in the mchr2 homozygous mutant. (G, H) Confocal section of double in situ/immunolabelling with pomca (G) or pomcb (H) in Tg(mch2:egfp) at 5 dpf, showing that only pomca is expressed in the pituitary gland. Dorsal view with anterior up (A, B). Ventral view with anterior up (C-F, I and J). Scale bars: 100 μm (A-D) or 10 μm (E, F, I and G).

(TIF)

Click here for additional data file.^{(2MB, tif)}

S4 Fig. pomca mutant displays normal countershading.

(A-D) Dark dorsums of 3-year-old pomca-/- and WT control sibling fish before (A, C) and after (B, D) epinephrine treatment to contract melanosomes. (E, F) Light ventrums of adult control (E) and pomca-/- (F) fish. (G) Quantification of dorsal melanophore and xanthophore counts of adult pomca-/- and WT control fish in 1mm² regions after epinephrine treatment. Difference in each category is statistically insignificant (n.s; p-value = 0.07). Data shown as mean ±standard error of the mean (SEM). Axis denote anterior (A) to posterior (P) positioning of the fish. Scale bar: 1 mm (A-F).

(TIF)

Click here for additional data file.^{(1.1MB, tif)}

S1 Data. Data used to generate Fig 2D.

Melanosome counts in ROI of black adapted control, Tg(hs:mch1) or Tg(hs:mch2) larvae at 7 dpf after heat-shock. The ROI is the area from the posterior of the eyes to the posterior of the hindbrain.

(XLSX)

Click here for additional data file.^{(13.5KB, xlsx)}

S2 Data. Data used to generate Fig 3D and 3G.

Melanosome counts in control or mchr2 homozygous mutant larvae at 7 dpf when either black adapted or white adapted in ROI from the posterior of the eyes to the posterior of the hindbrain.

(XLSX)

Click here for additional data file.^{(17.5KB, xlsx)}

S3 Data. Data used to generate Fig 4E.

Melanosome counts in black adapted control, mchr2 homozygous mutant, mchr2 homozygous mutant; Tg(hs:mch1) or mchr2 homozygous mutant; Tg(hs:mch2) larvae at 7 dpf in ROI. Non-significant differences as measured by t-test are labeled as “n.s.”

(XLSX)

Click here for additional data file.^{(13.8KB, xlsx)}

S4 Data. Data used to generate Fig 5F and 5K.

Melanosome counts in black adapted control or pomca homozygous mutant larvae and in white adapted control, pomca homozygous mutant, mchr2 homozygous mutant or pomca; mchr2 double homozygous mutant 7 dpf in ROI. Non-significant differences as measured by t-test are labeled as “n.s.”

(XLSX)

Click here for additional data file.^{(18.6KB, xlsx)}

S5 Data. Data used to generate S4G Fig.

Dorsal counts of melanophores and xanthophores of adult pomca-/- fish compared to counts in WT control fish in 1mm² regions after epinephrine treatment. Non-significant differences as measured by t-test are labeled as “n.s.”

(XLSX)

Click here for additional data file.^{(19.7KB, xlsx)}

Acknowledgments

We thank members of the Mourrain lab for insightful discussions and help. We are grateful to Dr. Gordon Wang for helpful advice for the pigmentation coverage analysis and to Dr. Neil C. Chi for the gift of the kdrl:mCherry transgenic line. We would also like to thank the Stanford CSIF Imaging platform.

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

This work was supported by grants (DK090065 and HL151576) from the National Institute of Health (https://www.nih.gov/) and the BrightFocus Foundation (https://www.brightfocus.org/). R.M was also supported by EMBO Long Term Fellowship (ALTF 413-2012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Mort RL, Jackson IJ, Patton EE. The melanocyte lineage in development and disease. Development 2015; 142(4):620–632. 10.1242/dev.106567 [DOI] [PMC free article] [PubMed] [Google Scholar]
2. Li Q, Frank M, Thisse CI, Thisse BV, Uitto J. Zebrafish: A model system to study heritable skin diseases. J. Invest. Dermatol. 2011; 131(3):565–571. 10.1038/jid.2010.388 [DOI] [PMC free article] [PubMed] [Google Scholar]
3. Logan DW, Burn SF, Jackson IJ. Regulation of pigmentation in zebrafish melanophores. Pigment Cell Res. 2006; 19(3):206–213. 10.1111/j.1600-0749.2006.00307.x [DOI] [PubMed] [Google Scholar]
4. Powell DL, García-Olazábal M, Keegan M, Reilly P, Du K, Díaz AP, et al. Natural hybridization reveals incompatible alleles that cause melanoma in swordtail fish. Science 2020; 368(6492):731–736. 10.1126/science.aba5216 [DOI] [PMC free article] [PubMed] [Google Scholar]
5. Lamason RL, Mohideen MP, Mest JR, Wong AC, Norton HL, Aros MC, et al. SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans. Science 2005; 310(5755):1782–1786. 10.1126/science.1116238 [DOI] [PubMed] [Google Scholar]
6. Basu CM, Iliescu FM, Möls M, Hill S, Tamang R, Chaubey G, et al. The light skin allele of SLC24A5 in South Asians and Europeans shares identity by descent. PLoS Genet. 2003; 9(11):e1003912 10.1371/journal.pgen.1003912 [DOI] [PMC free article] [PubMed] [Google Scholar]
7. Kawauchi H. Functions of melanin-concentrating hormone in fish. J. Exp. Zoolog. Part A Comp. Exp. Biol. 2006; 305(9):751–760. 10.1002/jez.a.310 [DOI] [PubMed] [Google Scholar]
8. Kawauchi H, Kawazoe I, Tsubokawa M, Kishida M, Baker BI. Characterization of melanin-concentrating hormone in chum salmon pituitaries. Nature 1983; 305(5932):321–323. 10.1038/305321a0 [DOI] [PubMed] [Google Scholar]
9. Takahashi A, Kawauchi H. Evolution of melanocortin systems in fish. Gen. Comp. Endocrinol. 2006; 148(1):85–94. 10.1016/j.ygcen.2005.09.020 [DOI] [PubMed] [Google Scholar]
10. Hoogduijin MJ, Ancans J, Suzuki I, Estdale S, Thody AJ. Melanin-concentrating hormone and its receptor are expressed and functional in human skin. Biochem. Biophys. Res. Commun. 2002; 296(3):698–701. 10.1016/S0006-291X(02)00932-4 [DOI] [PubMed] [Google Scholar]
11. Gottumukkala RV, Gavalas NG, Akhtar S, Metcalfe RA, Gawkrodger DJ, Haycock JW, et al. Function-blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients. Lab. Invest. 2006; 86(8):781–789. 10.1038/labinvest.3700438 [DOI] [PubMed] [Google Scholar]
12. Berman JR, Skariah G, Maro GS, Mignot E, Mourrain P. Characterization of two melanin-concentrating hormone genes in zebrafish reveals evolutionary and physiological links with the mammalian MCH system. J. Comp. Neurol. 2009; 517(5):695–710. 10.1002/cne.22171 [DOI] [PMC free article] [PubMed] [Google Scholar]
13. Ludwig DS, Mountjoy KG, Tatro JB, Gillette JA, Frederich RC, Flier JS, Maratos-Flier E. Melanin-concentrating hormone: a functional melanocortin antagonist in the hypothalamus. Am. J. Physiol. 1998; 274(4):E627–633. [DOI] [PubMed] [Google Scholar]
14. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002; 296(5573): 1636–1639. 10.1126/science.1071550 [DOI] [PubMed] [Google Scholar]
15. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat. Rev. Cancer 2007; 7:79–94. 10.1038/nrc2069 [DOI] [PubMed] [Google Scholar]
16. Wintzen M, and Gilchrest BA. Proopiomelanocortin, its derived peptides, and the skin. J. Invest. Dermatol. 1996; 106(1):3–10. 10.1111/1523-1747.ep12326950 [DOI] [PubMed] [Google Scholar]
17. Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012; 491 (7424) 449–453. 10.1038/nature11624 [DOI] [PMC free article] [PubMed] [Google Scholar]
18. Sheets L, Ransom DG, Mellgren EM, Johnson SL, Schnapp BJ. Zebrafish melanophilin facilitates melanosome dispersion by regulating dynein. Curr. Biol. 2007; 17(20):1721–1734. 10.1016/j.cub.2007.09.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
19. Amano M, Takahashi A. Melanin-concentrating hormone: A neuropeptide hormone affecting the relationship between photic environment and fish with special reference to background color and food intake regulation. Peptides 2009; 30(11):1979–1984. 10.1016/j.peptides.2009.05.022 [DOI] [PubMed] [Google Scholar]
20. Barber LD, Baker BI, Penny JC, Eberle AN. Melanin concentrating hormone inhibits the release of alpha MSH from teleost pituitary glands. Gen. Comp. Endocrinol. 1987; 65(1):79–86. 10.1016/0016-6480(87)90225-5 [DOI] [PubMed] [Google Scholar]
21. Baker BI. Melanin-concentration hormone updated functional considerations. Trends Endocrinol. Metab. 1994; 5(3):120–126. 10.1016/1043-2760(94)90093-0 [DOI] [PubMed] [Google Scholar]
22. Richardson J, Lundegard PR, Reynolds NL, Dorin JR, Porteous DJ, Jackson IJ, Patton EE. mc1r Pathway regulation of zebrafish melanosome dispersion. Zebrafish 2008; 5(4):289–295. 10.1089/zeb.2008.0541 [DOI] [PubMed] [Google Scholar]
23. Zhang C, Song Y, Thompson DA, Madonna MA, Millhauser GL, Toro S, et al. Pineal-specific agouti protein regulates teleost background adaptation. Proc. Natl. Acad. Sci. U.S.A. 2010; 107(47):20164–20171. 10.1073/pnas.1014941107 [DOI] [PMC free article] [PubMed] [Google Scholar]
24. Chung S, Saito Y, Civelli O. MCH receptors/gene structure-in vivo expression. Peptides 2009; 30(11):1985–1989. 10.1016/j.peptides.2009.07.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
25. Logan DW, Bryson-Richardson RJ, Pagán KE, Taylor MS, Currie PD, Jackson IJ. The structure and evolution of the melanocortin and MCH receptors in fish and mammals. Genomics 2003; 81(2):184–191. 10.1016/S0888-7543(02)00037-X [DOI] [PubMed] [Google Scholar]
26. Bagnara JT. Stimulation of Melanophores and Guanophores by Melanophore-Stimulating Hormone Peptides. Gen. Comp. Endocrinol. 1964; 4:290–294. 10.1016/0016-6480(64)90024-3 [DOI] [PubMed] [Google Scholar]
27. de Souza FS, Bumaschny VF, Low MJ, Rubinstein M. Subfunctionalization of expression and peptide domains following the ancient duplication of the proopiomelanocortin gene in teleost fishes. Mol. Biol. Evol. 2005; 22, 2417–2427. 10.1093/molbev/msi236 [DOI] [PubMed] [Google Scholar]
28. Liu NA, Huang H, Yang Z, Herzog W, Hammerschmidt M, Lin S, Melmed S. Pituitary corticotroph ontogeny and regulation in transgenic zebrafish. Mol. Endocrinol. 2003; 17, 959–966. 10.1210/me.2002-0392 [DOI] [PubMed] [Google Scholar]
29. Herzog W, Zeng X, Lele Z, Sonntag C, Ting JW, Chang CY, Hammerschmidt M. Adenohypophysis formation in the zebrafish and its dependence on sonic hedgehog. Dev. Biol. 2003; 254(1):36–49. 10.1016/S0012-1606(02)00124-0 [DOI] [PubMed] [Google Scholar]
30. Nasif S, de Souza FS, Gonzalez LE, Yamashita M, Orquera DP, Low MJ, Rubinstein M. Islet 1 specifies the identity of hypothalamic melanocortin neurons and is critical for normal food intake and adiposity in adulthood. Proc. Natl. Acad. Sci. U.S.A. 2015; 112(15):E1861–E1870. 10.1073/pnas.1500672112 [DOI] [PMC free article] [PubMed] [Google Scholar]
31. Cal L, Suarez-Bregua P, Braasch I, Irion U, Kelsh R, Cerdá-Reverter JM, Rottlant J. Loss-of-function mutations in the melanocortin 1 receptor cause disruption of dorso-ventral countershading in teleost fish. Pigment Cell and Melanoma Res. 2019; 32:817–828. 10.1111/pcmr.12806 [DOI] [PubMed] [Google Scholar]
32. Cal L, Suarez-Bregua P, Comesaña P, Owen J, Braasch I, Kelsh R, Cerdá-Reverter JM, Rottlant J. Countershading in zebrafish results from an Asip1 controlled dorsoventral gradient of pigment cell differentiation. Sci. Rep. 2019; 9:3449 10.1038/s41598-019-40251-z [DOI] [PMC free article] [PubMed] [Google Scholar]
33. Eves PC, MacNeil S, Haycock JW. alpha-Melanocyte stimulating hormone, inflammation, and human melanoma. Peptides 2006; 27(2):444–52. 10.1016/j.peptides.2005.01.027 [DOI] [PubMed] [Google Scholar]
34. Liu PY, Johansson O. Immunohistochemical evidence of α-, β-, and γ-melanocyte stimulating hormone in cutaneous malignant melanoma of nodular type. J. Dermatol. Sci. 1995; 10, 203–212. 10.1016/0923-1811(95)00405-H [DOI] [PubMed] [Google Scholar]
35. Nagahama M, Funasaka Y, Fernandez-Frez ML, Ohashi A, Chakraborty AK, Ueda M, Ichihashi M. Immunoreactivity of alpha-melanocyte-stimulating hormone, adrenocorticotrophic hormone and beta-endorphin in cutaneous malignant melanoma and benign melanocytic naevi. Br. J. Dermatol. 1998; 138(6):981–985. 10.1046/j.1365-2133.1998.02263.x [DOI] [PubMed] [Google Scholar]
36. Kemp EH, Weetman AP. Melanin-concentrating hormone and melanin-concentrating hormone receptors in mammalian skin physiopathology. Peptides 2009; 30(11):2071–2075. 10.1016/j.peptides.2009.04.025 [DOI] [PubMed] [Google Scholar]
37. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet 2015; 386(9988):74–84. 10.1016/S0140-6736(14)60763-7 [DOI] [PubMed] [Google Scholar]
38. Gottumukkala RV, Gavalas NG, Akhtar S, Metcalfe RA, Gawkrodger DJ, Haycock JW, et al. Function-blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients. Lab. Invest. 2006; 86(8):781–789. 10.1038/labinvest.3700438 [DOI] [PubMed] [Google Scholar]
39. Kemp EH, Waterman EA, Hawes BE, O’Neill K, Gottumukkala RV, Gawkrodger DJ, et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J. Clin. Invest. 2002; 109(7): 923–930. 10.1172/JCI14643 [DOI] [PMC free article] [PubMed] [Google Scholar]
40. Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature 2007; 445(7130):843–850. 10.1038/nature05660 [DOI] [PubMed] [Google Scholar]
41. Krauss J, Geiger-Rudolph S, Koch I, Nusslein-Volhard C, Irion U. A dominant mutation in tyrp1A leads to melanophore death in zebrafish. Pigment Cell Melanoma Res. 2014; 27(5): 827–830. [DOI] [PubMed] [Google Scholar]
42. Eskova A, Frohnhöfer HG, Nusslein-Volhard C, Irion U. Galanin Signaling in the brain regulates color pattern formation in zebrafish. Curr. Biol. 2020; 30: 298–303. 10.1016/j.cub.2019.11.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
43. Leung LC, Wang GX, Madelaine R, Skariah G, Kawakami K, Deisseroth K, Urban AE, Mourrain P. Neural signatures of sleep in zebrafish. Nature. 2019; 571: 198–204. 10.1038/s41586-019-1336-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
44. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, et al. Agouti protein is an antagonist of the melanocyte-stimulating hormone receptor. Nature 1994; 371: 799–802. 10.1038/371799a0 [DOI] [PubMed] [Google Scholar]
45. Siracusa LD. The agouti gene: turned on to yellow. Trends Genet. 1994; 10: 423–428. 10.1016/0168-9525(94)90112-0 [DOI] [PubMed] [Google Scholar]
46. Norris BJ, Whan VA. A gene duplication affecting expression of the ovine ASIP gene is responsible for white and black sheep. Genome Res. 2008; 18: 1282–1293. 10.1101/gr.072090.107 [DOI] [PMC free article] [PubMed] [Google Scholar]
47. Fontanesi L, Rustempašić A, Brka M, Russo V. Analysis of polymorphisms in the agouti signalling protein (ASIP) and melanocortin 1 receptor (MC1R) genes and association with coat colours in two Pramenka sheep types. Small Rumin. Res. 2012; 105: 89–96. 10.1016/j.smallrumres.2012.02.008 [DOI] [Google Scholar]
48. Chandramohan B, Renieri C, La Manna V, La Terza A. The alpaca agouti gene: genomic locus, transcripts, and causative mutations of eumelanic and pheomelanic coat color. Gene 2013; 521: 303–310. 10.1016/j.gene.2013.03.060 [DOI] [PubMed] [Google Scholar]
49. Manceau M, Domingues VS, Mallarino R, Hoekstra HE. The developmental role of agouti in color pattern evolution. Science 2011; 331: 1062–1065. 10.1126/science.1200684 [DOI] [PubMed] [Google Scholar]
50. Ilnytska O, Argyropoulos G. The role of the agouti-related protein in energy balance regulation. Cell Mol. Life Sci. 2008; 65(17):2721–2731. 10.1007/s00018-008-8104-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
51. Morselli LL, Claflin KE, Cui H, Grob JL. Control of energy expenditure by AgRP neurons of the arcuate nucleus: neurocircuitry, signaling pathways, and angiotensin. Curr. Hypertens. Rep. 2008; 20(3):25 10.1007/s11906-018-0824-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
52. Guillot R, Ceinos RM, Cal R, Rotllant J, Cerdá-Reverter JM. Transient ectopic overexpression of agouti-signalling protein 1 (Asip1) induces pigment anomalies in flatfish. PLoS One 2012; 7(12):e48526 10.1371/journal.pone.0048526 [DOI] [PMC free article] [PubMed] [Google Scholar]
53. Cal L, Suarez-Brgua P, Cerdá-Reverter JM, Braasch I, Rotllant J. Fish pigmentation and the melanocortin system. Comp. Biochem. Physiol., Part A Mol. Integr. Physiol. 2017; 211:26–33. 10.1016/j.cbpa.2017.06.001 [DOI] [PubMed] [Google Scholar]
54. Cerdá-Reverter JM, Peter RE. Endogenous melanocortin antagonist in fish: structure, brain mapping, and regulation by fasting of the goldfish agouti-related protein gene. Endocrinology 2003; 144(10): 4552–61. 10.1210/en.2003-0453 [DOI] [PubMed] [Google Scholar]
55. Cerdá-Reverter JM, Haitina T, Schiöth HB, Peter RE. Gene structure of the goldfish agouti-signaling protein: A putative role in the dorsal-ventral pigmente pattern of fish. Endocrinology 2005; 146(3): 1597–1610. 10.1210/en.2004-1346 [DOI] [PubMed] [Google Scholar]
56. Kurokawa T, Murashita K, Uji S. Characterization and tissue distribution of multiple agouti-family genes in pufferfish, Takifugu rubripes. Peptides 2006; 27: 3165–3175. 10.1016/j.peptides.2006.09.013 [DOI] [PubMed] [Google Scholar]
57. Ceinos RM, Guillot R, Kelsh RN, Cerdá-Reverter JM, Rotllant J. Pigment patterns in adult fish result from superimposition of two largely independent pigmentation mechanisms. Pigment Cell Melanoma Res. 2015; 28: 196–209. 10.1111/pcmr.12335 [DOI] [PubMed] [Google Scholar]
58. Devi LA and Brady LS. Dimerization of G-protein coupled receptors. Neuropsychopharmacology. 2000; 23: S3–S4. 10.1016/S0893-133X(00)00154-8 [DOI] [PubMed] [Google Scholar]
59. Terrillon S and Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep. 2004; 5(1): 30–34. 10.1038/sj.embor.7400052 [DOI] [PMC free article] [PubMed] [Google Scholar]
60. Murray, Adan, Walker, Baker, Thody, Nijenhuis, Yukitake, Wilson. Melanin-concentrating hormone, melanocortin receptors and regulation of luteinizing hormone release. J. Neuroendocrinol. 2000; 12(3): 217–223. 10.1046/j.1365-2826.2000.00440.x [DOI] [PubMed] [Google Scholar]
61. Castrucci AM, Hadley ME, Wilkes BC, Zechel C, Hruby VJ. Melanin concentrating hormone exhibits both MSH and MCH activites on individual melanophores. Life Sci. 1987; 40(19): 1845–1851. 10.1016/0024-3205(87)90041-5 [DOI] [PubMed] [Google Scholar]
62. Gröneveld D, Balm PH, Bonga SE. Biphasic effect of MCH on -MSH release from the tilapia (Oreochromis mossambicus) pituitary. Peptides. 1995; 16(5): 945–949. 10.1016/0196-9781(95)00063-P [DOI] [PubMed] [Google Scholar]
63. Chhajlani V. Distribution of cDNA for melanocortin receptor subtypes in human tissues. Biochem Mol. Biol. Int. 1996; 38(1): 73–80. [PubMed] [Google Scholar]
64. Thiboutot D, Sivarajah A, Gilliland K, Cong Z, Clawson G. The melanocortin 5 receptor is expressed in human sebaceous glands and rat preputial cells. J. Invest. Dermatol. 2000; 115: 614–619. 10.1046/j.1523-1747.2000.00094.x [DOI] [PubMed] [Google Scholar]
65. Kobayashi Y, Hamamoto A, Takahashi A, Saito Y. Dimerization of melanocortin receptor 1 (MC1R) and MC5R creates a ligand-dependent signal modulation: Potential participation in physiological color change in the flounder. Gen. Comp. Endocrinol. 2016; 230-231: 103–109. 10.1016/j.ygcen.2016.04.008 [DOI] [PubMed] [Google Scholar]
66. Sanchez-Laorden BL, Sanchez-Mas J, Martinez-Alonso E, Martinez-Menarguez JA, Garcia-Borron JC, Jimenez-Cervantes C. Dimerization of the human melanocortin 1 receptor: functional consequences and dominant-negative effects. J. Invest Dermatol. 2006a; 126: 172–181. 10.1038/sj.jid.5700036 [DOI] [PubMed] [Google Scholar]
67. Piechowski CL, Rediger A, Lagemann C, Muhlhaus J, Muller A, Pratzka J, et al. Inhibition of melanocortin-4 receptor dimerization by substitutions in intracellular loop 2. J. Mol. Endocrinol. 2013; 51(1): 109–118. 10.1530/JME-13-0061 [DOI] [PubMed] [Google Scholar]
68. Mandrika I, Petrovska R, Wikberg J. Melanocortin receptors form constitutive homo- and heterodimers. Biochem. Biophys. Res. Commun. 2005; 326(2): 349–354. 10.1016/j.bbrc.2004.11.036 [DOI] [PubMed] [Google Scholar]
69. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. Dev. Dyn. 1995; 203(3):253–310. 10.1002/aja.1002030302 [DOI] [PubMed] [Google Scholar]
70. Chi NC, Shaw RM, De Val S, Kang G, Jan LY, Black BL, Stainier DY. Foxn4 directly regulates tbx2b expression and atrioventricular canal formation. Genes Dev. 2008; 22(6):734–739. 10.1101/gad.1629408 [DOI] [PMC free article] [PubMed] [Google Scholar]
71. Varshney GK, Pei W, LaFave MC, Idol J, Xu L, Gallardo V, et al. High-throughput gene targeting and phenotyping in zebrafish using CRISPR/Cas9. Genome Res. 2015; 25(7):1030–1042. 10.1101/gr.186379.114 [DOI] [PMC free article] [PubMed] [Google Scholar]
72. Kwan KM, Fujimoto E, Grabher C, Mangum BD, Hardy ME, Campbell DS, et al. The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs. Dev. Dyn. 2007; 236(11):3088–3099. 10.1002/dvdy.21343 [DOI] [PubMed] [Google Scholar]
73. Oxtoby E, Jowett T. Cloning of the zebrafish krox-20 gene (krx-20) and its expression during hindbrain development. Nucleic Acids Res. 1993; 21(5):1087–1095. 10.1093/nar/21.5.1087 [DOI] [PMC free article] [PubMed] [Google Scholar]
74. Masai I, Heisenberg C, Barth KA, Macdonald R, Adamek S, Wilson SW. floating head and masterblind regulate neuronal patterning in the roof of the forebrain. Neuron 1997; 18(1):43–57. 10.1016/S0896-6273(01)80045-3 [DOI] [PubMed] [Google Scholar]

PLoS Genet. doi: 10.1371/journal.pgen.1009244.r001

Decision Letter 0

Ian J Jackson, Gregory P Copenhaver

17 Aug 2020

Dear Dr Mourrain,

Thank you very much for submitting your Research Article entitled 'Genetic deciphering of the antagonistic activities of the melanin-concentrating hormone and melanocortin pathways in skin pigmentation' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the current manuscript. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review again a much-revised version. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

In particular you should provide more detail on the pomca mutants as requested by Reviewer 1, and give due consideration to the comments of Reviewer 2 regarding Figure S3 and the abnormal appearance of the the larva in S3H and the different age of the larvae in this Figure. In addition the comments of Reviewer 3 regarding ligand cross-binding and receptor dimerisation should be taken into account. If quantification of tyrosinase and pomca expression, as requested by Reviewer 2, is available it should be included.

I would also suggest that you reduce the emphasis on the relevance of MCH to human pigmentation. There is no evidence that the MCH system plays any role in mammalian pigmentation. As you know, mice lack MCHR2 completely, and KO of MCHR1 has no pigmentary phenotype.

Please also note that one of the reviewers commented that "data for the graphs in figs 2, 3, 4 and 5 are not provided in spreadsheet form as supporting information" - this must be addressed in your revision in accordance with PLOS Genetics' open access data policy.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to plosgenetics@plos.org.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our Submission Checklist.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our guidelines.

Please be aware that our data availability policy requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.

We note that numerical data for Figures 2, 3, 4 and 5 should be included as supplementary data.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

PLOS has incorporated Similarity Check, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.

[LINK]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Ian J. Jackson

Guest Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: In the manuscript entitled ’Genetic deciphering of the antagonistic activities of the melanin-concentrating hormone and melanocortin pathways in skin pigmentation’ Madelaine et al. show that background adaptation in zebrafish, i.e. aggregation or dispersal of melanosomes within melanophores, is regulated by two opposing signaling systems. The authors show that projections from melanin-concentrating hormone (MCH) producing neurons are found in close proximity to blood vessels in the pituitary, suggesting that this is the way the peptides are released to exert their functions in the periphery. Overexpression of the two MCH orthologs induces the aggregation of melanosomes in larval zebrafish, and the authors show that the peptide hormones act specifically via one of the receptors, Mchr2. Mutations in the gene encoding this receptor affect background adaptation not only in larvae but also in adult fish. In addition they show that the opposite process, i.e. melanosome dispersal, is defective in larvae with mutations in the pomca gene, which presumably affects melanocortin signaling via the receptor Mc1r. Surprisingly, while mchr2-/- is epistatic over pomca-/- in larvae, this is no longer the case in adult fish, which hints at a more complex regulation of the process.

The manuscript is generally well written and easy to understand; I only think that the introduction and the discussion could be a little bit more concise.

The results are presented in a clear fashion and the conclusions are sound.

The only point, which I feel should be clarified concerns the pomca mutants generated and the relation to Mc1r signaling:

- the authors describe that two small deletions in different exons were produced, but they fail to indicate which allele (or combination) the animals shown in figures 4 and 5 actually carry.

- are the phenotypes of animals homozygous for either mutant allele identical?

- how does the pomca k.o. phenotype compare to the published mc1r k.o. phenotype?

- especially, what is the number and distribution of pigment cells in the adult mutant fish? Is it similar to wild type, meaning only background adaptation in the mutant larvae is affected and there is no adult phenotype? Or, is it similar to mc1r mutants, which have not been described to be defective in background adaptation, but rather in counter shading? This could possibly provide further clues to understanding the complexity of the system.

Reviewer #2: PGENETICS-D-20-01069

'Genetic deciphering of the antagonistic activities of the melanin-concentrating hormone and melanocortin pathways in skin pigmentation'

The authors use loss of function mutants for mchr1a/b, mchr2 and pomca, plus transgenic reporters of MCH peptide expression, to test the hypothesis that antagonistic interactions between MCH and MSH signalling control background adaptation (i.e. the rapid movement of melanosomes along the microtubular cytoskeleton to change the overall darkness of the body) in a fish genetic model, zebrafish.

The authors begin by generating a transgenic reporter of mch2 expression in zebrafish, revealing projection of MCH2-expressing hypothalamic neurons to the pituitary, and specifically their projection to regions in the vicinity of the associated vasculature. As presented the relative positions of the areas shown in each panel are difficult for the non-expert to interpret. An interpretative diagram of brain structure and the zones shown would be invaluable.

They then used 2 distinct transgenic lines to drive heat shock-mediated overexpression of MCH1 and MCH2 respectively, compared to control non-transgenic fish that were also heat shocked. Each peptide was capable of reversing melanosome dispersion of early larval fish kept on a dark background, when expressed by heat shock.

To assess which of the candidate MCHR might mediate the MCH effect, the authors generated mchr1a mchr1b and mchr2 knockout lines, generated by CRISPR/Cas-9 or TILLING methodologies. Both 7 dpf and adult mchr2 knockouts show a pronounced constitutive dispersion of melanin, under both light and dark background conditions, as expected of the background adaptation-associated receptor. As expected, this effect was not affected by over-expression of mch1 or mch2. In contrast, neither single nor double mutants of mchr1 genes gave a pigment dispersion phenotype.

As a prelude to assessing the endogenous role of POMCA in melanosome dispersion, the authors assess tyrosinase expression in melanocytes as a method for evaluating whether melanocyte differentiation is normal. However, this requires a quantitative assessment and whole mount ISH technique they use is, at best, seim-quantitative. The authors should supplement this panel with qRT-PCR quantitation of tyrosinase expression in the body (i.e a region excluding the eyes). Likewise, they assess pomca expression in mchr2 mutants by WISH, and by immunofluorescence, to conclude that MCHR2 knockout does not affect pomca or MSH peptide levels. Again, since they are drawing quantitative conclusions from inherently semi-quantitative techniques, more sensitive quantitative data would be useful to supplement these observations.

To test the hypothesis that melanosome dispersion depends upon POMC/a-MSH, the authors used transgenic overexpression of POMCA. Their demonstration of enhanced dispersion (Fig. S3G,H) is unclear. The larva shown in panel H seems to be deformed, with abnormal distribution of melanocytes. This makes it very difficult to assess the dispersion of melanosomes. Closeups of individual melanocytes in morphologically unaffected regions, and quantitation of the degree of dispersion (as used throughout the rest of the paper) should be provided to justify the conclusion reached. Also, the fish shown are much younger than in the rest of the study (3 dpf) and hence close to the time when background adaptation first appears. Hence, comparison of control and transgenic fish on both white and dark backgrounds should be used to control for this.

To more directly test the role for POMC, the authors generated a pomca mutant. They demonstrate both the absence of immunofluorescently-detectable aMSH and the expected failure of melanosome dispersion under light-adapted conditions. Intriguingly, an mchr2; pomca double knockout shows a 7 dpf larval phenotype indistinguishable from that of mchr2 alone, indicating that factors other than aMSH can promote melanosome dispersion. The authors observe that this changes gradually as the fish age, so that adult double mutants show the pomca knockout phenotype, indicating that another factor can substitute for MCH at this stage. These observations are intriguing and setup a series of future studies as outlined in the Discussion.

In summary, this is a conceptually simple, but convincing, well-controlled and nicely documented demonstration of the specific MCH signalling components underpinning zebrafish background adaptation.

Minor points

1) Fig. 1 legend. Outline in panel A needs explanation.

2) Fig. 2D. x axis label font is too small. Enlarge so is readily legible.

3) Fig. 3 legend. ‘ROI’ is not defined, although presumably ‘Region of Interest’. Also, this region should be indicated/described briefly.

4) Fig. 5 title. As written, it does not quite make sense to me. Authors should revise.

Reviewer #3: In this study, Romaine and colleagues investigate the genetic mechanisms underlying skin color in teleosts (zebrafish) using transgenic models and pigmentation analysis.

These new original genetic evidence for an antagonistic role of MCH and alpha-MSH in skin pigmentation are convincing and confirm old antibody-based studies. The manuscript is well written and data are rigorously presented and analysed. I did appreciate some of the control experiment (e.g., double transgenic). The discussion of the results is appropriate. Thus, I have several comments and questions that are listed below in order of appearance in the MS.

The authors first map the axonal projections of MCH neurons using a transgenic line Tg(mch2:egfp) which nicely confirm original immunostaining study in salmon from the '80s. Further they show that both MCH1 and MCH 2 share pigment aggregation properties. At this point, I was wondering if MCH1 and MCH2-expressing neurons project to other targets outside the pineal gland with some possible distinction amongst targets - this should be mentioned somewhere in the MS, at least for MCH2-expressing cells, and if not reported previously.

To study the receptor subtypes involved in this regulation, they then generate mchr1a, mchr1b and mchr2 KO mutants (CRISPR/Cas or TILLING) and found that only mchr2 is involved in skin pigmentation. I did appreciate the careful analysis of the double mutant [mchr1a-mchr1b] controls which did not show neither changes in pigmentation. Interestingly, control experiments using mch1 or mch2 over-expression in the mchr2 mutant confirmed the need of a functional MCHR2 to reduce melanin dispersion. This is a very convincing result.

Based on previous studies showing an antagonistic action between MCH and alpha-MSH, the authors generate a KO of pomca (POMC precursor gene) fish that is not able to adapt to a black background. Yet, knock-out of pomca in the mchr2 mutant does not rescue the mchr2 and double mutant phenotype were different than the larval stage. The authors interpret these data as "... additional factors other than α-MSH can promote melanosome dispersion in the mchr2 mutant genetic background in larvae" and "...the inability of the adult mchr2 mutant to adapt to a white background is due to the predominant activity of the melanocortin pathway".

This is puzzling and I was wondering whether this could be to a low affinity cross-binding between peptide ligand (MCH/alpha-MSH - e.g., MSH onto MCHR2) and the remaining receptors. Furthermore, are the MCH and alpha-MSH peptides known to bind a single receptor (MCH or MSH receptors subtypes) with low affinity ? Could that explain this phenotype ?

Homodimerization and heterodimerization are frequent amongst GPCRs - since those receptors are co-expressed in skin melanophores, could such phenomenon affect the intracellular pathway activation and, ultimately the skin pigmentation in the larval stage of these mutants?

Does a change in gene transcripts, peptide or receptor expression may explain the larval versus adult different phenotypes ? In other words, are there known changes of these across development including 'peptide-receptor' affinity ? If so, could the authors provide such experimental data ? that would really strengthen the study.

Figure 2A, 3 A,B, 5 G,H all show control conditions, however, the pigmentation shape is quite different - where does that come from ? is this due to the background exposure? is there any type of correction for that across quantifications ?

Minors:

-many results section start with a rationale that often repeat some parts of the introduction - repetition should be avoided.

-avoid the use the form "to our knowledge" multiple times.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: No: data for the graphs in figs 2, 3, 4 and 5 are not provided in spreadsheet form as supporting information

Reviewer #2: Yes

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Uwe Irion

Reviewer #2: No

Reviewer #3: Yes: Antoine Adamantidis

PLoS Genet. 2020 Dec 10;16(12):e1009244. doi: 10.1371/journal.pgen.1009244.r002

Author response to Decision Letter 0

15 Oct 2020

Attachment

Submitted filename: Response to All Reviewers 20201012.pdf

Click here for additional data file.^{(315KB, pdf)}

PLoS Genet. doi: 10.1371/journal.pgen.1009244.r003

Decision Letter 1

Ian J Jackson, Gregory P Copenhaver

30 Oct 2020

Dear Dr Mourrain,

We are pleased to inform you that your manuscript entitled "Genetic deciphering of the antagonistic activities of the melanin-concentrating hormone and melanocortin pathways in skin pigmentation" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Could you please note the two minor comments from Reviewer 2, below, and make appropriate changes to the manuscript as you prepare your final draft for the production team (the editorial team will not need to reevaluate).

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you’ve already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosgenetics@plos.org.

In the meantime, please log into Editorial Manager at https://www.editorialmanager.com/pgenetics/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about one way to make your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Ian J. Jackson

Guest Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

www.plosgenetics.org

Twitter: @PLOSGenetics

----------------------------------------------------

Comments from the reviewers (if applicable):

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: The authors adequately addressed the points I raised previously; the manuscript should be published.

Reviewer #2: 'Genetic deciphering of the antagonistic activities of the melanin-concentrating hormone and melanocortin pathways in skin pigmentation'

The authors have dealt appropriately with the referees’ comments. I have only a couple of minor suggestions:

Fig. 2D and Fig. 3D legends. Authors refer to ‘bottom’ of eyes and hindbrain, but more correct would be ‘posterior’. However, I wonder if the region might be best described as ‘those melanocytes in the anterior Dorsal Stripe lying dorsal to the hindbrain’?

p. 11 ‘premature apparition of a stop codon’ is used; better would be ‘appearance of a premature stop codon’

Reviewer #3: The authors have satisfactorily answered all my concerns.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Uwe Irion

Reviewer #2: Yes: Robert N. Kelsh

Reviewer #3: Yes: Antoine Adamantidis

----------------------------------------------------

Data Deposition

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the Dryad Digital Repository. As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our website.

The following link will take you to the Dryad record for your article, so you won't have to re‐enter its bibliographic information, and can upload your files directly:

http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-20-01069R1

More information about depositing data in Dryad is available at http://www.datadryad.org/depositing. If you experience any difficulties in submitting your data, please contact help@datadryad.org for support.

Additionally, please be aware that our data availability policy requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

----------------------------------------------------

Press Queries

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper's publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there's anything the journal should know or you'd like more information, please get in touch via plosgenetics@plos.org.

PLoS Genet. doi: 10.1371/journal.pgen.1009244.r004

Acceptance letter

Ian J Jackson, Gregory P Copenhaver

1 Dec 2020

PGENETICS-D-20-01069R1

Genetic deciphering of the antagonistic activities of the melanin-concentrating hormone and melanocortin pathways in skin pigmentation

Dear Dr Mourrain,

We are pleased to inform you that your manuscript entitled "Genetic deciphering of the antagonistic activities of the melanin-concentrating hormone and melanocortin pathways in skin pigmentation" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Nicola Davies

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom

plosgenetics@plos.org | +44 (0) 1223-442823

plosgenetics.org | Twitter: @PLOSGenetics

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Fig. mch2 reporter line demonstrates that Mch axons reach the pituitary gland.

(TIF)

Click here for additional data file.^{(1.9MB, tif)}

S2 Fig. mchr1a and mchr1b are not involved in melanosome organization.

(TIF)

Click here for additional data file.^{(1.6MB, tif)}

S3 Fig. pomca expression in the posterior pituitary gland.

(TIF)

Click here for additional data file.^{(2MB, tif)}

S4 Fig. pomca mutant displays normal countershading.

(TIF)

Click here for additional data file.^{(1.1MB, tif)}

S1 Data. Data used to generate Fig 2D.

Melanosome counts in ROI of black adapted control, Tg(hs:mch1) or Tg(hs:mch2) larvae at 7 dpf after heat-shock. The ROI is the area from the posterior of the eyes to the posterior of the hindbrain.

(XLSX)

Click here for additional data file.^{(13.5KB, xlsx)}

S2 Data. Data used to generate Fig 3D and 3G.

Melanosome counts in control or mchr2 homozygous mutant larvae at 7 dpf when either black adapted or white adapted in ROI from the posterior of the eyes to the posterior of the hindbrain.

(XLSX)

Click here for additional data file.^{(17.5KB, xlsx)}

S3 Data. Data used to generate Fig 4E.

(XLSX)

Click here for additional data file.^{(13.8KB, xlsx)}

S4 Data. Data used to generate Fig 5F and 5K.

(XLSX)

Click here for additional data file.^{(18.6KB, xlsx)}

S5 Data. Data used to generate S4G Fig.

(XLSX)

Click here for additional data file.^{(19.7KB, xlsx)}

Attachment

Submitted filename: Response to All Reviewers 20201012.pdf

Click here for additional data file.^{(315KB, pdf)}

Data Availability Statement

All relevant data are within the manuscript and its Supporting information files.

[pgen.1009244.ref001] 1. Mort RL, Jackson IJ, Patton EE. The melanocyte lineage in development and disease. Development 2015; 142(4):620–632. 10.1242/dev.106567 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref002] 2. Li Q, Frank M, Thisse CI, Thisse BV, Uitto J. Zebrafish: A model system to study heritable skin diseases. J. Invest. Dermatol. 2011; 131(3):565–571. 10.1038/jid.2010.388 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref003] 3. Logan DW, Burn SF, Jackson IJ. Regulation of pigmentation in zebrafish melanophores. Pigment Cell Res. 2006; 19(3):206–213. 10.1111/j.1600-0749.2006.00307.x [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref004] 4. Powell DL, García-Olazábal M, Keegan M, Reilly P, Du K, Díaz AP, et al. Natural hybridization reveals incompatible alleles that cause melanoma in swordtail fish. Science 2020; 368(6492):731–736. 10.1126/science.aba5216 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref005] 5. Lamason RL, Mohideen MP, Mest JR, Wong AC, Norton HL, Aros MC, et al. SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans. Science 2005; 310(5755):1782–1786. 10.1126/science.1116238 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref006] 6. Basu CM, Iliescu FM, Möls M, Hill S, Tamang R, Chaubey G, et al. The light skin allele of SLC24A5 in South Asians and Europeans shares identity by descent. PLoS Genet. 2003; 9(11):e1003912 10.1371/journal.pgen.1003912 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref007] 7. Kawauchi H. Functions of melanin-concentrating hormone in fish. J. Exp. Zoolog. Part A Comp. Exp. Biol. 2006; 305(9):751–760. 10.1002/jez.a.310 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref008] 8. Kawauchi H, Kawazoe I, Tsubokawa M, Kishida M, Baker BI. Characterization of melanin-concentrating hormone in chum salmon pituitaries. Nature 1983; 305(5932):321–323. 10.1038/305321a0 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref009] 9. Takahashi A, Kawauchi H. Evolution of melanocortin systems in fish. Gen. Comp. Endocrinol. 2006; 148(1):85–94. 10.1016/j.ygcen.2005.09.020 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref010] 10. Hoogduijin MJ, Ancans J, Suzuki I, Estdale S, Thody AJ. Melanin-concentrating hormone and its receptor are expressed and functional in human skin. Biochem. Biophys. Res. Commun. 2002; 296(3):698–701. 10.1016/S0006-291X(02)00932-4 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref011] 11. Gottumukkala RV, Gavalas NG, Akhtar S, Metcalfe RA, Gawkrodger DJ, Haycock JW, et al. Function-blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients. Lab. Invest. 2006; 86(8):781–789. 10.1038/labinvest.3700438 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref012] 12. Berman JR, Skariah G, Maro GS, Mignot E, Mourrain P. Characterization of two melanin-concentrating hormone genes in zebrafish reveals evolutionary and physiological links with the mammalian MCH system. J. Comp. Neurol. 2009; 517(5):695–710. 10.1002/cne.22171 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref013] 13. Ludwig DS, Mountjoy KG, Tatro JB, Gillette JA, Frederich RC, Flier JS, Maratos-Flier E. Melanin-concentrating hormone: a functional melanocortin antagonist in the hypothalamus. Am. J. Physiol. 1998; 274(4):E627–633. [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref014] 14. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002; 296(5573): 1636–1639. 10.1126/science.1071550 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref015] 15. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat. Rev. Cancer 2007; 7:79–94. 10.1038/nrc2069 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref016] 16. Wintzen M, and Gilchrest BA. Proopiomelanocortin, its derived peptides, and the skin. J. Invest. Dermatol. 1996; 106(1):3–10. 10.1111/1523-1747.ep12326950 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref017] 17. Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012; 491 (7424) 449–453. 10.1038/nature11624 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref018] 18. Sheets L, Ransom DG, Mellgren EM, Johnson SL, Schnapp BJ. Zebrafish melanophilin facilitates melanosome dispersion by regulating dynein. Curr. Biol. 2007; 17(20):1721–1734. 10.1016/j.cub.2007.09.028 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref019] 19. Amano M, Takahashi A. Melanin-concentrating hormone: A neuropeptide hormone affecting the relationship between photic environment and fish with special reference to background color and food intake regulation. Peptides 2009; 30(11):1979–1984. 10.1016/j.peptides.2009.05.022 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref020] 20. Barber LD, Baker BI, Penny JC, Eberle AN. Melanin concentrating hormone inhibits the release of alpha MSH from teleost pituitary glands. Gen. Comp. Endocrinol. 1987; 65(1):79–86. 10.1016/0016-6480(87)90225-5 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref021] 21. Baker BI. Melanin-concentration hormone updated functional considerations. Trends Endocrinol. Metab. 1994; 5(3):120–126. 10.1016/1043-2760(94)90093-0 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref022] 22. Richardson J, Lundegard PR, Reynolds NL, Dorin JR, Porteous DJ, Jackson IJ, Patton EE. mc1r Pathway regulation of zebrafish melanosome dispersion. Zebrafish 2008; 5(4):289–295. 10.1089/zeb.2008.0541 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref023] 23. Zhang C, Song Y, Thompson DA, Madonna MA, Millhauser GL, Toro S, et al. Pineal-specific agouti protein regulates teleost background adaptation. Proc. Natl. Acad. Sci. U.S.A. 2010; 107(47):20164–20171. 10.1073/pnas.1014941107 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref024] 24. Chung S, Saito Y, Civelli O. MCH receptors/gene structure-in vivo expression. Peptides 2009; 30(11):1985–1989. 10.1016/j.peptides.2009.07.017 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref025] 25. Logan DW, Bryson-Richardson RJ, Pagán KE, Taylor MS, Currie PD, Jackson IJ. The structure and evolution of the melanocortin and MCH receptors in fish and mammals. Genomics 2003; 81(2):184–191. 10.1016/S0888-7543(02)00037-X [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref026] 26. Bagnara JT. Stimulation of Melanophores and Guanophores by Melanophore-Stimulating Hormone Peptides. Gen. Comp. Endocrinol. 1964; 4:290–294. 10.1016/0016-6480(64)90024-3 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref027] 27. de Souza FS, Bumaschny VF, Low MJ, Rubinstein M. Subfunctionalization of expression and peptide domains following the ancient duplication of the proopiomelanocortin gene in teleost fishes. Mol. Biol. Evol. 2005; 22, 2417–2427. 10.1093/molbev/msi236 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref028] 28. Liu NA, Huang H, Yang Z, Herzog W, Hammerschmidt M, Lin S, Melmed S. Pituitary corticotroph ontogeny and regulation in transgenic zebrafish. Mol. Endocrinol. 2003; 17, 959–966. 10.1210/me.2002-0392 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref029] 29. Herzog W, Zeng X, Lele Z, Sonntag C, Ting JW, Chang CY, Hammerschmidt M. Adenohypophysis formation in the zebrafish and its dependence on sonic hedgehog. Dev. Biol. 2003; 254(1):36–49. 10.1016/S0012-1606(02)00124-0 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref030] 30. Nasif S, de Souza FS, Gonzalez LE, Yamashita M, Orquera DP, Low MJ, Rubinstein M. Islet 1 specifies the identity of hypothalamic melanocortin neurons and is critical for normal food intake and adiposity in adulthood. Proc. Natl. Acad. Sci. U.S.A. 2015; 112(15):E1861–E1870. 10.1073/pnas.1500672112 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref031] 31. Cal L, Suarez-Bregua P, Braasch I, Irion U, Kelsh R, Cerdá-Reverter JM, Rottlant J. Loss-of-function mutations in the melanocortin 1 receptor cause disruption of dorso-ventral countershading in teleost fish. Pigment Cell and Melanoma Res. 2019; 32:817–828. 10.1111/pcmr.12806 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref032] 32. Cal L, Suarez-Bregua P, Comesaña P, Owen J, Braasch I, Kelsh R, Cerdá-Reverter JM, Rottlant J. Countershading in zebrafish results from an Asip1 controlled dorsoventral gradient of pigment cell differentiation. Sci. Rep. 2019; 9:3449 10.1038/s41598-019-40251-z [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref033] 33. Eves PC, MacNeil S, Haycock JW. alpha-Melanocyte stimulating hormone, inflammation, and human melanoma. Peptides 2006; 27(2):444–52. 10.1016/j.peptides.2005.01.027 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref034] 34. Liu PY, Johansson O. Immunohistochemical evidence of α-, β-, and γ-melanocyte stimulating hormone in cutaneous malignant melanoma of nodular type. J. Dermatol. Sci. 1995; 10, 203–212. 10.1016/0923-1811(95)00405-H [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref035] 35. Nagahama M, Funasaka Y, Fernandez-Frez ML, Ohashi A, Chakraborty AK, Ueda M, Ichihashi M. Immunoreactivity of alpha-melanocyte-stimulating hormone, adrenocorticotrophic hormone and beta-endorphin in cutaneous malignant melanoma and benign melanocytic naevi. Br. J. Dermatol. 1998; 138(6):981–985. 10.1046/j.1365-2133.1998.02263.x [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref036] 36. Kemp EH, Weetman AP. Melanin-concentrating hormone and melanin-concentrating hormone receptors in mammalian skin physiopathology. Peptides 2009; 30(11):2071–2075. 10.1016/j.peptides.2009.04.025 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref037] 37. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet 2015; 386(9988):74–84. 10.1016/S0140-6736(14)60763-7 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref038] 38. Gottumukkala RV, Gavalas NG, Akhtar S, Metcalfe RA, Gawkrodger DJ, Haycock JW, et al. Function-blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients. Lab. Invest. 2006; 86(8):781–789. 10.1038/labinvest.3700438 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref039] 39. Kemp EH, Waterman EA, Hawes BE, O’Neill K, Gottumukkala RV, Gawkrodger DJ, et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J. Clin. Invest. 2002; 109(7): 923–930. 10.1172/JCI14643 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref040] 40. Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature 2007; 445(7130):843–850. 10.1038/nature05660 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref041] 41. Krauss J, Geiger-Rudolph S, Koch I, Nusslein-Volhard C, Irion U. A dominant mutation in tyrp1A leads to melanophore death in zebrafish. Pigment Cell Melanoma Res. 2014; 27(5): 827–830. [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref042] 42. Eskova A, Frohnhöfer HG, Nusslein-Volhard C, Irion U. Galanin Signaling in the brain regulates color pattern formation in zebrafish. Curr. Biol. 2020; 30: 298–303. 10.1016/j.cub.2019.11.033 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref043] 43. Leung LC, Wang GX, Madelaine R, Skariah G, Kawakami K, Deisseroth K, Urban AE, Mourrain P. Neural signatures of sleep in zebrafish. Nature. 2019; 571: 198–204. 10.1038/s41586-019-1336-7 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref044] 44. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, et al. Agouti protein is an antagonist of the melanocyte-stimulating hormone receptor. Nature 1994; 371: 799–802. 10.1038/371799a0 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref045] 45. Siracusa LD. The agouti gene: turned on to yellow. Trends Genet. 1994; 10: 423–428. 10.1016/0168-9525(94)90112-0 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref046] 46. Norris BJ, Whan VA. A gene duplication affecting expression of the ovine ASIP gene is responsible for white and black sheep. Genome Res. 2008; 18: 1282–1293. 10.1101/gr.072090.107 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref047] 47. Fontanesi L, Rustempašić A, Brka M, Russo V. Analysis of polymorphisms in the agouti signalling protein (ASIP) and melanocortin 1 receptor (MC1R) genes and association with coat colours in two Pramenka sheep types. Small Rumin. Res. 2012; 105: 89–96. 10.1016/j.smallrumres.2012.02.008 [DOI] [Google Scholar]

[pgen.1009244.ref048] 48. Chandramohan B, Renieri C, La Manna V, La Terza A. The alpaca agouti gene: genomic locus, transcripts, and causative mutations of eumelanic and pheomelanic coat color. Gene 2013; 521: 303–310. 10.1016/j.gene.2013.03.060 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref049] 49. Manceau M, Domingues VS, Mallarino R, Hoekstra HE. The developmental role of agouti in color pattern evolution. Science 2011; 331: 1062–1065. 10.1126/science.1200684 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref050] 50. Ilnytska O, Argyropoulos G. The role of the agouti-related protein in energy balance regulation. Cell Mol. Life Sci. 2008; 65(17):2721–2731. 10.1007/s00018-008-8104-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref051] 51. Morselli LL, Claflin KE, Cui H, Grob JL. Control of energy expenditure by AgRP neurons of the arcuate nucleus: neurocircuitry, signaling pathways, and angiotensin. Curr. Hypertens. Rep. 2008; 20(3):25 10.1007/s11906-018-0824-8 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref052] 52. Guillot R, Ceinos RM, Cal R, Rotllant J, Cerdá-Reverter JM. Transient ectopic overexpression of agouti-signalling protein 1 (Asip1) induces pigment anomalies in flatfish. PLoS One 2012; 7(12):e48526 10.1371/journal.pone.0048526 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref053] 53. Cal L, Suarez-Brgua P, Cerdá-Reverter JM, Braasch I, Rotllant J. Fish pigmentation and the melanocortin system. Comp. Biochem. Physiol., Part A Mol. Integr. Physiol. 2017; 211:26–33. 10.1016/j.cbpa.2017.06.001 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref054] 54. Cerdá-Reverter JM, Peter RE. Endogenous melanocortin antagonist in fish: structure, brain mapping, and regulation by fasting of the goldfish agouti-related protein gene. Endocrinology 2003; 144(10): 4552–61. 10.1210/en.2003-0453 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref055] 55. Cerdá-Reverter JM, Haitina T, Schiöth HB, Peter RE. Gene structure of the goldfish agouti-signaling protein: A putative role in the dorsal-ventral pigmente pattern of fish. Endocrinology 2005; 146(3): 1597–1610. 10.1210/en.2004-1346 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref056] 56. Kurokawa T, Murashita K, Uji S. Characterization and tissue distribution of multiple agouti-family genes in pufferfish, Takifugu rubripes. Peptides 2006; 27: 3165–3175. 10.1016/j.peptides.2006.09.013 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref057] 57. Ceinos RM, Guillot R, Kelsh RN, Cerdá-Reverter JM, Rotllant J. Pigment patterns in adult fish result from superimposition of two largely independent pigmentation mechanisms. Pigment Cell Melanoma Res. 2015; 28: 196–209. 10.1111/pcmr.12335 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref058] 58. Devi LA and Brady LS. Dimerization of G-protein coupled receptors. Neuropsychopharmacology. 2000; 23: S3–S4. 10.1016/S0893-133X(00)00154-8 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref059] 59. Terrillon S and Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep. 2004; 5(1): 30–34. 10.1038/sj.embor.7400052 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref060] 60. Murray, Adan, Walker, Baker, Thody, Nijenhuis, Yukitake, Wilson. Melanin-concentrating hormone, melanocortin receptors and regulation of luteinizing hormone release. J. Neuroendocrinol. 2000; 12(3): 217–223. 10.1046/j.1365-2826.2000.00440.x [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref061] 61. Castrucci AM, Hadley ME, Wilkes BC, Zechel C, Hruby VJ. Melanin concentrating hormone exhibits both MSH and MCH activites on individual melanophores. Life Sci. 1987; 40(19): 1845–1851. 10.1016/0024-3205(87)90041-5 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref062] 62. Gröneveld D, Balm PH, Bonga SE. Biphasic effect of MCH on -MSH release from the tilapia (Oreochromis mossambicus) pituitary. Peptides. 1995; 16(5): 945–949. 10.1016/0196-9781(95)00063-P [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref063] 63. Chhajlani V. Distribution of cDNA for melanocortin receptor subtypes in human tissues. Biochem Mol. Biol. Int. 1996; 38(1): 73–80. [PubMed] [Google Scholar]

[pgen.1009244.ref064] 64. Thiboutot D, Sivarajah A, Gilliland K, Cong Z, Clawson G. The melanocortin 5 receptor is expressed in human sebaceous glands and rat preputial cells. J. Invest. Dermatol. 2000; 115: 614–619. 10.1046/j.1523-1747.2000.00094.x [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref065] 65. Kobayashi Y, Hamamoto A, Takahashi A, Saito Y. Dimerization of melanocortin receptor 1 (MC1R) and MC5R creates a ligand-dependent signal modulation: Potential participation in physiological color change in the flounder. Gen. Comp. Endocrinol. 2016; 230-231: 103–109. 10.1016/j.ygcen.2016.04.008 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref066] 66. Sanchez-Laorden BL, Sanchez-Mas J, Martinez-Alonso E, Martinez-Menarguez JA, Garcia-Borron JC, Jimenez-Cervantes C. Dimerization of the human melanocortin 1 receptor: functional consequences and dominant-negative effects. J. Invest Dermatol. 2006a; 126: 172–181. 10.1038/sj.jid.5700036 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref067] 67. Piechowski CL, Rediger A, Lagemann C, Muhlhaus J, Muller A, Pratzka J, et al. Inhibition of melanocortin-4 receptor dimerization by substitutions in intracellular loop 2. J. Mol. Endocrinol. 2013; 51(1): 109–118. 10.1530/JME-13-0061 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref068] 68. Mandrika I, Petrovska R, Wikberg J. Melanocortin receptors form constitutive homo- and heterodimers. Biochem. Biophys. Res. Commun. 2005; 326(2): 349–354. 10.1016/j.bbrc.2004.11.036 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref069] 69. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. Dev. Dyn. 1995; 203(3):253–310. 10.1002/aja.1002030302 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref070] 70. Chi NC, Shaw RM, De Val S, Kang G, Jan LY, Black BL, Stainier DY. Foxn4 directly regulates tbx2b expression and atrioventricular canal formation. Genes Dev. 2008; 22(6):734–739. 10.1101/gad.1629408 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref071] 71. Varshney GK, Pei W, LaFave MC, Idol J, Xu L, Gallardo V, et al. High-throughput gene targeting and phenotyping in zebrafish using CRISPR/Cas9. Genome Res. 2015; 25(7):1030–1042. 10.1101/gr.186379.114 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref072] 72. Kwan KM, Fujimoto E, Grabher C, Mangum BD, Hardy ME, Campbell DS, et al. The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs. Dev. Dyn. 2007; 236(11):3088–3099. 10.1002/dvdy.21343 [DOI] [PubMed] [Google Scholar]

[pgen.1009244.ref073] 73. Oxtoby E, Jowett T. Cloning of the zebrafish krox-20 gene (krx-20) and its expression during hindbrain development. Nucleic Acids Res. 1993; 21(5):1087–1095. 10.1093/nar/21.5.1087 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pgen.1009244.ref074] 74. Masai I, Heisenberg C, Barth KA, Macdonald R, Adamek S, Wilson SW. floating head and masterblind regulate neuronal patterning in the roof of the forebrain. Neuron 1997; 18(1):43–57. 10.1016/S0896-6273(01)80045-3 [DOI] [PubMed] [Google Scholar]

PERMALINK

Genetic deciphering of the antagonistic activities of the melanin-concentrating hormone and melanocortin pathways in skin pigmentation

Romain Madelaine

Keri J Ngo

Gemini Skariah

Philippe Mourrain

Roles

Abstract

Author summary

Introduction

Results

Mch axons projects to the pituitary gland

Fig 1. The hypothalamic MCH2 peptide interacts with the neurohypophysis.

Mch1 and Mch2 overexpression reduce skin pigmentation

Fig 2. Mammalian orthologous MCH2 peptide induces melanosome contraction.

MCHR2 is required for melanosome aggregation and background adaptation

Fig 3. Loss of Mchr2-dependent signaling leads to melanosome dispersion.

Fig 4. MCH-dependent melanosome contraction relies on Mchr2 activity.

Antagonistic activity between MCH and α-MSH controls skin pigmentation

Fig 5. pomca loss of function leads to melanosomes contraction, but is not sufficient to rescue the mchr2 mutant phenotype in larvae.

Fig 6. MCH signaling counteracts melanocortin system activity to promote melanosome contraction in adult zebrafish.

Discussion

Materials and methods

Fish lines and developmental conditions

Ethics statement

CRISPR/Cas-9 generation of zebrafish mutants

Plasmid construction and transgenic line establishment

In situ hybridization and immunostaining

Image acquisition and quantification of pigmentation coverage

Melanophore and xanthophore counts

Supporting information

Acknowledgments

Data Availability

Funding Statement

References

Decision Letter 0

Ian J Jackson

Gregory P Copenhaver

Roles

Author response to Decision Letter 0

Decision Letter 1

Ian J Jackson

Gregory P Copenhaver

Roles

Acceptance letter

Ian J Jackson

Gregory P Copenhaver

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases